A Phase 1 interventional study of MRTX849 and BI 1701963 in Advanced Cancer, Metastatic Cancer and Malignant Neoplasm of Colon, sponsored by Mirati Therapeutics Inc.. Terminated at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-12-16.
Sponsored by Mirati Therapeutics Inc. (part of Bristol-Myers Squibb) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 50 studies in Neoplasm Metastasis by Bristol-Myers Squibb — 1 open to participants now, 8 under way, 1 of them phase 3. Neoplasm Metastasis · Bristol-Myers Squibb.
Among the 50 studies in Neoplasm Metastasis by Bristol-Myers Squibb, this one is the 41st largest by enrollment of the 44 interventional ones that give a count, is one of 4 that started in 2021, is one of 16 in phase 1, and was the 39th registered.
4,046 studies on the registry are indexed under Neoplasm Metastasis; 889 are open to participants now.
Browse Neoplasm Metastasis studies →1 of the 50 studies in Neoplasm Metastasis by Bristol-Myers Squibb is open now, in 11 countries. Recruiting first, the newest first:
Turning Point Therapeutics, Inc. · Sites in United States, Australia, Canada and 8 more countries
Ages up to 25
By country, each count listing its studies:
Of the 690 Neoplasm Metastasis studies recruiting now, 537 (78%) set no upper age limit and 97 (14%) stop at 75 or younger; 48 take children under 18; 18 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
50 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 25 · Phase 2 23 · Phase 3 7
First in 2000; this study’s year is marked. 4 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 7 is below the median of 50 across 3,271 interventional studies indexed under Neoplasm Metastasis.
Median enrollment 66 across the 44 interventional studies, 509 across the 5 observational. Of the 39 that completed or were terminated, 14 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Mirati Therapeutics Inc., one of the names counted as Bristol-Myers Squibb. Under that name alone:
Mirati Therapeutics Inc. is the lead sponsor of 51 studies on the registry; 3 are open to participants now.
Of its 20 completed or terminated interventional studies of FDA-regulated products, 4 (20%) have results posted.
1 of the studies in Neoplasm Metastasis by Bristol-Myers Squibb that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05165264Bristol-Myers SquibbA Study of Nivolumab Plus Chemotherapy in First Line Treatment of Adult Participants With Advanced or Metastatic Gastric Cancer | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 50 studies in Neoplasm Metastasis by Bristol-Myers Squibb, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will evaluate safety, tolerability, drug levels, molecular effects and clinical activity of MRTX849 (adagrasib) in combination with BI 1701963 in patients with advanced solid tumors that have a KRAS G12C mutation.
This study will evaluate safety, tolerability, pharmacokinetics, metabolites, pharmacodynamics and clinical activity of MRTX849 (adagrasib) in combination with BI 1701963 in patients with advanced solid tumors with a KRAS G12C mutation. MRTX849 is an orally available small molecule inhibitor of KRAS G12C and BI 1701963 is a SOS1 pan-KRAS inhibitor.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Dose escalation of MRTX849 and BI 1701963 to determine maximum tolerated dose in combination
Drug: MRTX849 · Drug: BI 1701963
Expansion cohorts in NSCLC and CRC patients to ensure sufficient safety experience, pharmacokinetic information, and early evidence of clinical activity of MRTX849 in combination with BI 1701963
Drug: MRTX849 · Drug: BI 1701963
KRAS G12C inhibitor
Also known as: KRAS G12C inhibitor, adagrasib
SOS1 Inhibitor
Also known as: SOS1 Inhibitor
Characterize the number of patients with treatment emergent adverse events of the combination regimen in patients with advanced solid tumor malignancies with KRAS G12C mutation
Number of participants with treatment related adverse events
Time frame: 20 months
Evaluate Pharmacokinetics of the combination regimen
Blood plasma concentration
Time frame: 20 months
Establish Maximum Tolerated Dose
Number of patients with dose limiting toxicity
Time frame: 12 months
Evaluate preliminary clinical activity of the combination regimen
Objective response rate in accordance with Response Evaluation Criteria in Solid Tumors (RECIST)
Time frame: 20 months
Plan to share: No
No publications or documents are linked to this record.
Ran from Jul 2021 to primary completion in Nov 2022, 15 months.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Adagrasib · Pan-KRAS Inhibitor BI 1701963